Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.

CONCLUSIONS: These results provide a preclinical rationale for improved treatment modalities using olaparib as an effective radiosensitizer in HGSOC, particularly in tumors with BRCA1-deficiencies.
PMID: 30025822 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - July 16, 2018 Category: Cancer & Oncology Authors: Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C Tags: Gynecol Oncol Source Type: research